Cited 2 times in
Effect of sequential release of sirolimus and rosuvastatin using silk fibroin microneedle to prevent intimal hyperplasia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김정환 | - |
dc.contributor.author | 윤영남 | - |
dc.date.accessioned | 2024-01-16T01:59:51Z | - |
dc.date.available | 2024-01-16T01:59:51Z | - |
dc.date.issued | 2023-12 | - |
dc.identifier.issn | 0753-3322 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/197817 | - |
dc.description.abstract | Intimal hyperplasia (IH) is a major cause of vascular restenosis after bypass surgery, which progresses as a series of processes from the acute to chronic stage in response to endothelial damage during bypass grafting. A strategic localized drug delivery system that reflects the pathophysiology of IH and minimizes systemic side effects is necessary. In this study, the sequential release of sirolimus, a mechanistic target of rapamycin (mTOR) inhibitor, and statin, an HMG-COA inhibitor, was realized as a silk fibroin-based microneedle device in vivo. The released sirolimus in the acute stage reduced neointima (NI) and vascular fibrosis through mTOR inhibition. Furthermore, rosuvastatin, which was continuously released from the acute to chronic stage, reduced vascular stiffness and apoptosis through the inactivation of Yes-associated protein (YAP). The sequential release of sirolimus and rosuvastatin confirmed the synergistic treatment effects on vascular inflammation, VSMC proliferation, and ECM degradation remodeling through the inhibition of transforming growth factor (TGF)-beta/NF-κB pathway. These results demonstrate the therapeutic effect on preventing restenosis with sufficient vascular elasticity and significantly reduced IH in response to endothelial damage. Therefore, this study suggests a promising strategy for treating coronary artery disease through localized drug delivery of customized drug combinations. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English, French | - |
dc.publisher | Elsevier | - |
dc.relation.isPartOf | BIOMEDICINE & PHARMACOTHERAPY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Cell Proliferation | - |
dc.subject.MESH | Disease Models, Animal | - |
dc.subject.MESH | Fibroins* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hyperplasia | - |
dc.subject.MESH | Rosuvastatin Calcium / pharmacology | - |
dc.subject.MESH | Sirolimus* / pharmacology | - |
dc.subject.MESH | TOR Serine-Threonine Kinases | - |
dc.title | Effect of sequential release of sirolimus and rosuvastatin using silk fibroin microneedle to prevent intimal hyperplasia | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Thoracic and Cardiovascular Surgery (흉부외과학교실) | - |
dc.contributor.googleauthor | Eui Hwa Jang | - |
dc.contributor.googleauthor | Ji-Yeon Ryu | - |
dc.contributor.googleauthor | Jung-Hwan Kim | - |
dc.contributor.googleauthor | JiYong Lee | - |
dc.contributor.googleauthor | WonHyoung Ryu | - |
dc.contributor.googleauthor | Young-Nam Youn | - |
dc.identifier.doi | 10.1016/j.biopha.2023.115702 | - |
dc.contributor.localId | A00905 | - |
dc.contributor.localId | A02576 | - |
dc.relation.journalcode | J00322 | - |
dc.identifier.eissn | 1950-6007 | - |
dc.identifier.pmid | 37837879 | - |
dc.subject.keyword | Bypass surgery | - |
dc.subject.keyword | Intimal hyperplasia | - |
dc.subject.keyword | Localized drug delivery | - |
dc.subject.keyword | Microneedle | - |
dc.subject.keyword | Silk fibroin | - |
dc.contributor.alternativeName | Kim, Jung Hwan | - |
dc.contributor.affiliatedAuthor | 김정환 | - |
dc.contributor.affiliatedAuthor | 윤영남 | - |
dc.citation.volume | 168 | - |
dc.citation.startPage | 115702 | - |
dc.identifier.bibliographicCitation | BIOMEDICINE & PHARMACOTHERAPY, Vol.168 : 115702, 2023-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.